RESEARCH ARTICLE
Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis
Yoshiyuki Morishita 1, *, Eiji Kusano 2, Daisuke Nagata 1
Article Information
Identifiers and Pagination:
Year: 2014Volume: 8
First Page: 6
Last Page: 11
Publisher ID: TOCMJ-8-6
DOI: 10.2174/1874192401408010006
Article History:
Received Date: 1/1/2013Revision Received Date: 1/1/2014
Acceptance Date: 5/1/2014
Electronic publication date: 7 /2/2014
Collection year: 2013

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
The renin-angiotensin-aldosterone system (RAAS) blockers have been widely used in chronic kidney disease patients undergoing hemodialysis; however, whether RAAS blockers have beneficial effects for cardiovascular disease in those patients has not been fully defined. This review focuses on the effects of RAAS blockers in chronic kidney disease undergoing hemodialysis for cardiovascular disease.